{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:19:18Z","timestamp":1790439558486,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.omtm.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:44:44Z","timestamp":1517406284000},"page":"210-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["The Pharmacology of T Cell Therapies"],"prefix":"10.1016","volume":"8","author":[{"given":"Michael C.","family":"Milone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay G.","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2018.01.010_bib1","unstructured":"Novartis AG. (2017). Kymriah package insert. https:\/\/www.fda.gov\/downloads\/UCM573941.pdf."},{"key":"10.1016\/j.omtm.2018.01.010_bib2","unstructured":"Kite Pharma, Inc. (2017). Yescarta package insert. https:\/\/www.fda.gov\/downloads\/UCM581226.pdf."},{"key":"10.1016\/j.omtm.2018.01.010_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.omtm.2018.01.010_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00262-002-0315-1","article-title":"Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma","volume":"51","author":"Dr\u00e9no","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtm.2018.01.010_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.1999.17.8.2521","article-title":"Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma","volume":"17","author":"Figlin","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omtm.2018.01.010_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtm.2018.01.010_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.omtm.2018.01.010_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.coph.2015.09.004","article-title":"Retrovirus-based vectors for transient and permanent cell modification","volume":"24","author":"Schott","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omtm.2018.01.010_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aah6192","article-title":"Lentiviral vectors, two decades later","volume":"353","author":"Naldini","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtm.2018.01.010_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1089\/hum.2017.128","article-title":"Transposons: moving forward from preclinical studies to clinical trials","volume":"28","author":"Tipanee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2018.01.010_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR\u00a0into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T\u00a0cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-cell genomics unveils critical regulators of Th17 cell pathogenicity","volume":"163","author":"Gaublomme","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2018.01.010_bib16","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1182\/blood-2016-05-716480","article-title":"A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation","volume":"128","author":"Nestorowa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib17","unstructured":"Novartis. (2017). Tisagenlecleucel. Report of the Oncologic Drugs Advisory Committee Meeting, U.S. Food & Drug Administration. November 9, 2017, BLA 125646. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM566166.pdf."},{"key":"10.1016\/j.omtm.2018.01.010_bib18","unstructured":"Motz, G., Bushman, F.D., Fraietta, J.A., June, C.H., Melenhorst, J.J., Nobles, C.L., and Young, R.M. March 23, 2017. Car t\u00a0cell therapies with enhanced efficacy. U.S. patent WO2017049166 A1."},{"key":"10.1016\/j.omtm.2018.01.010_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1089\/hum.2005.16.1241","article-title":"Silencing and variegation of gammaretrovirus and lentivirus vectors","volume":"16","author":"Ellis","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib21","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib22","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T\u00a0cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib24","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib25","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T\u00a0cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.omtm.2018.01.010_bib26","article-title":"Optimizing chimeric antigen receptor (CAR) T\u00a0cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Frey","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib27","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood.V88.8.3223.bloodjournal8883223","article-title":"CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies","volume":"88","author":"Mavroudis","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T\u00a0cells derived from central memory cells establishes persistent T\u00a0cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2018.01.010_bib29","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T\u00a0cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V128.22.57.57","article-title":"Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia","volume":"128","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2018.01.010_bib32","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib33","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib34","doi-asserted-by":"crossref","first-page":"e4749","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in\u00a0vivo survival of adoptively transferred CD8 T\u00a0cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2018.01.010_bib35","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T\u00a0cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib37","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.177.7.4521","article-title":"Homeostatic proliferation as an isolated variable reverses CD8+ T\u00a0cell anergy and promotes tumor rejection","volume":"177","author":"Brown","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2018.01.010_bib38","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1158\/1078-0432.CCR-07-4696","article-title":"Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma","volume":"14","author":"Kline","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2018.01.010_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1172\/JCI1348","article-title":"Importance of cyclophosphamide-induced bystander effect on T\u00a0cells for a successful tumor eradication in response to adoptive immunotherapy in mice","volume":"101","author":"Proietti","year":"1998","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2018.01.010_bib40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2018.01.010_bib41","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI32205","article-title":"Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T\u00a0cells via TLR4 signaling","volume":"117","author":"Paulos","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2018.01.010_bib42","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2012-02-411124","article-title":"Depletion of radio-resistant regulatory T\u00a0cells enhances antitumor immunity during recovery from lymphopenia","volume":"120","author":"Baba","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib43","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.4049\/jimmunol.1200274","article-title":"Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T\u00a0cell therapy in a murine model of melanoma","volume":"189","author":"Kodumudi","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2018.01.010_bib44","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib45","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib46","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T\u00a0cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2018.01.010_bib47","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/ijc.25960","article-title":"Costimulation by chimeric antigen receptors revisited the T\u00a0cell antitumor response benefits from combined CD28-OX40 signalling","volume":"129","author":"Hombach","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtm.2018.01.010_bib48","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor t\u00a0cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib49","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T\u00a0cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtm.2018.01.010_bib50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13238-017-0411-9","article-title":"Increasing the safety and efficacy of chimeric antigen receptor T\u00a0cell therapy","volume":"8","author":"Li","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.omtm.2018.01.010_bib51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T\u00a0cell therapy: challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2018.01.010_bib52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T\u00a0cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib53","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T\u00a0cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2018.01.010_bib54","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T\u00a0cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2018.01.010_bib55","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T\u00a0cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2018.01.010_bib56","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T\u00a0cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2018.01.010_bib57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtm.2018.01.010_bib58","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib59","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T\u00a0cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib60","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T\u00a0cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib61","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib62","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T\u00a0cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T\u00a0cells (CART-BCMA) for multiple myeloma (mm): initial safety and efficacy from a phase I study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib65","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V126.23.3778.3778","article-title":"First-in-man CD123-specific chimeric antigen receptor-modified T\u00a0cells for the treatment of refractory acute myeloid leukemia","volume":"126","author":"Luo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CJI.0000000000000160","article-title":"Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells","volume":"40","author":"Tanyi","year":"2017","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2018.01.010_bib67","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib68","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtm.2018.01.010_bib69","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib70","first-page":"880","article-title":"The promise of chimeric antigen receptor T-cell therapy","volume":"30","author":"Frey","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.omtm.2018.01.010_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression\u00a0and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2018.01.010_bib73","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T\u00a0cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib74","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2018.01.010_bib77","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T\u00a0cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib78","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived\u00a0HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T\u00a0cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib79","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1089\/hum.2009.146","article-title":"T cell receptor gene therapy for cancer","volume":"20","author":"Schmitt","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.01.010_bib80","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19095","article-title":"Domain-swapped T\u00a0cell receptors improve the safety of TCR gene therapy","volume":"5","author":"Bethune","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2018.01.010_bib81","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2018.01.010_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib83","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T\u00a0cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2018.01.010_bib84","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2018.01.010_bib85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2018.01.010_bib86","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2018.01.010_bib87","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent anti-leukemia activities of chimeric antigen receptor-modified t\u00a0cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.omtm.2018.01.010_bib88","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t\u00a0cells after failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.omtm.2018.01.010_bib89","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2018.01.010_bib90","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T\u00a0cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2018.01.010_bib91","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118300111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118300111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T14:53:28Z","timestamp":1603724008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050118300111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":91,"alternative-id":["S2329050118300111"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2018.01.010","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacology of T Cell Therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors.","name":"copyright","label":"Copyright"}]}}